Prostate Cancer

Novartis Reports Positive Health-Related Quality of Life Data for 177Lu-PSMA-617 Radioligand Therapy in Patients with Advanced Prostate Cancer at ESMO 2021 September 17, 2021

Time management: Improving the timing of post-prostatectomy radiotherapy, clinical trials, and knowledge translation. September 17, 2021

Exercise as a supportive care strategy in men with prostate cancer receiving androgen deprivation therapy at a regional cancer centre: a survey of patients and clinicians. September 17, 2021

Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. September 17, 2021

Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. September 17, 2021

Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi-phased study of prostate cancer. September 16, 2021

Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI. September 16, 2021

Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. September 16, 2021

A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. September 16, 2021

Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. September 16, 2021

Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy September 15, 2021

NUBEQA® (darolutamide) Impact on Local Symptoms Evaluated in Men with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) September 15, 2021

Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. September 15, 2021

Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer. September 15, 2021

Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant. September 15, 2021

The Prognosis of Radical Prostatectomy, External Beam Radiotherapy plus Brachytherapy, and External Beam Radiotherapy Alone for Patients above 70 Years with Very High-Risk Prostate Cancer: A Population-Matched Study. September 15, 2021

Lantheus and RefleXion Announce Development and Commercialization Collaboration with the Potential to Improve Future Prostate Cancer Treatment September 14, 2021

Lantheus Announces Addition of PSMA PET Imaging Agent to the National Comprehensive Cancer Network® (NCCN) Guidelines for Prostate Cancer September 14, 2021

Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer. September 14, 2021

Systematic biopsy should not be omitted in the era of combined magnetic resonance imaging/ultrasound fusion-guided biopsies of the prostate. September 14, 2021

Page 1 of 1173